BridgeBio Pharma reported a third-quarter loss of $0.42 per share, beating the consensus estimate of -$0.60 by 30.0% and improving 55.8% from a year ago, when the company lost $0.95 per share. Revenue of $353.17 million topped the $296.58 million consensus by 19.1% and grew 192.6% year over year. Those are big numbers, but the quality of the beat deserves scrutiny. A one-time $75.0 million BEYONTTRA sales milestone from Bayer is larger than the entire revenue surprise. Meanwhile, U.S. Attruby, the engine of the equity story, is still growing but is adding dollars at a visibly slower pace. That is the central tension: the P&L and the pipeline are moving decisively forward while the core franchise's growth curve is flattening.
On the surface, the operating line looks transformed. The loss from operations shrank to $11.6 million from $107.1 million in the second quarter and $145.2 million a year ago. Management flagged two reasons that result should not be treated as a run-rate. The first is the Bayer milestone. The second is favorable timing of launch spending, with operating expenses expected to catch up in the fourth quarter. SG&A still climbed $63.2 million year over year to $200.9 million, and R&D rose $30.6 million to $143.5 million. Below the operating line, $42.3 million of noncash interest on deferred royalty obligations and $26.3 million of preferred dividends and accretion pushed the loss attributable to common stockholders to $83.0 million. Royalty revenue is a cleaner positive. It rose to $20.5 million from $15.4 million in Q2 and $9.5 million in Q1, and management described BEYONTTRA as the leading brand in Europe.
U.S. Attruby net revenue reached $253.2 million, up 134% year over year and now annualizing above $1 billion. Growth was again led by treatment-naïve patients, with Attruby gaining share of new starts. The sequential trajectory, however, has bent. Quarter-over-quarter growth slowed from 35% in Q4 2025 to 24%, roughly 23%, and now 14%. The dollar add of about $31 million trailed the $35 million-plus increments of prior quarters. The more consequential shift is in management's language. On the Q2 call, the company spoke of quarterly adds of "$35 million or more" and a "positive second derivative" within six to nine months. It now frames $25-30 million per quarter as the right near-term base and characterizes the slowdown as normal launch variance. Competitive pressure is also building. Better-resourced rivals are targeting long-tail prescribers, more than 60% of whom have not tried Attruby, which likely means more spending to defend share. UnitedHealth's Vyndamax preference also remains in place, although appeal approval rates exceed 90%.
The pipeline offers a credible offset. BBP-418 for LGMD2I/R9 has a November 27 PDUFA date, product already in the channel, and management confidence in a traditional full approval. Infigratinib's February 4, 2027 PDUFA arrives ahead of the mid-2027 timing given last quarter. Encaleret's May 8 date is unchanged, and confirmed ADH1 patients rose to more than 600 from about 500. RECLAIM-HP topline data in chronic hypoparathyroidism, an estimated 200,000-patient opportunity, were pulled in to early 2028. Fresh real-world comparisons favoring acoramidis over tafamidis strengthen Attruby's clinical narrative, including an 18% lower composite risk and 25% lower all-cause hospitalization in the Epic COSMOS analysis. Two developments cut the other way. BBP-418's EU filing slips to the first half of 2028 because regulators want 36-month FORTIFY data, and Ascendis has filed a citizen petition challenging infigratinib's safety. The $1.5 billion cash position funds all three launches, but it was built with $934 million of preferred stock and $632.5 million of 2033 notes. The $548 million of 2027 notes has also moved into current liabilities.
The market had already turned skeptical before the report. Shares fell 18.6% from the $87.02 open after the August release to $70.82. They peaked at $89.49 that first day and bottomed at $62.86 on October 14. The stock entered earnings 12.7% above that low but 20.9% below the high and 2.7% under its $72.82 200-day moving average. Investor sentiment swung sharply, from a clearly positive 0.38 to roughly neutral at -0.03. Earnings Whispers trend readings are mixed: sequential growth and momentum are positive, while price and AVWAP trends remain negative.
The bottom line is that BridgeBio delivered a headline beat that overstates near-term operating leverage, because the milestone and deferred spending will not repeat. The quarter also forced a reset of Attruby growth expectations that bears can legitimately exploit. Still, the call kept the larger story intact: a $1 billion-plus franchise, rising royalties, and three potential first-in-disease approvals within seven months. With sentiment already deflated and shares trading just below their long-term average, the next leg likely hinges less on Attruby's quarterly adds and more on how cleanly BBP-418 clears the FDA in November.